Stockholm, December 20, 2024

Picture from left to right: Rolf Rosenvinge, CEO Foresights; Anna Averud, CEO Truesec Group; Marcus Murray, Founder Truesec.

Truesec announces the acquisition of Foresights, a company specializing in cyber advisory and intelligence.

The combination of Truesec and Foresights will provide decision-makers and organizations with unique insights and tools to manage business risks.

35% of European enterprises will have dedicated budgets for cyber risk mitigation for the first time this year. This trend is driven by increased cyber threats and the need to protect against revenue loss, operational disruption, and reputational damage caused by these threats

Organizations are facing rapidly increased risks due to the current geopolitical landscape, digitization, and maturing cyber threats.

Decision makers are in urgent need of efficient solutions to navigate and mitigate cyber risks. The acquisition of Foresights is a key component in Truesec’s strategy to provide sustainability and resilience to organizations.

Foresights has an impressive track record and unique expertise in the industry. Together, Truesec and Foresights will provide unparalleled insights, advisory, and intelligence to the market.

“The market is seeking executive advisory and intelligence solutions within cyber. Everyone deserves maximum value for their cyber investments. We are very pleased to welcome Foresights to Truesec,” says Anna Averud, CEO Truesec Group.

Foresights’ founder and CEO, Rolf Rosenvinge, adds, “By becoming part of Truesec, we can combine our strategic insights and understanding of business risk with Truesec’s deep technical expertise and extensive knowledge of the cyber threat landscape. This mix will give our customers a true advantage against adversaries”.

The acquisition means that Foresights employees will be integrated into Truesec’s organization, and collaboration between the two companies will begin immediately.

Contacts

Anna Averud 
CEO, Truesec Group
Email: anna.averud@truesec.com 
Phone: +46-70 918 30 48

Jennie Mattar 
CMO, Truesec Group
Email: jennie.mattar@truesec.com 
Phone: +46-72 858 88 78 

IK Partners (“IK”) is pleased to announce that the IK Small Cap II (“IK SC II”) Fund has signed an agreement to sell its stake in Mecenat Group AB (“Mecenat” or “the Group”), a leading marketing and brand awareness platform, to Inflexion. Financial terms of the transaction are not disclosed.

Founded in 1998 and headquartered in Gothenburg, Sweden, Mecenat is a digital marketing platform which connects students, young professionals/alumni and seniors with well-known brands by providing access to exclusive offerings, career services and relevant events. Operating across five main business areas in Sweden and Finland, the Group takes pride in connecting almost three million members with more than 700 local and global brands, creating synergetic exchanges in the areas of brand building, unique discount offerings and marketing. Mecenat’s platform spans diverse industries, including Technology, Fashion, Travel and Entertainment and includes key partners such as Apple, Zalando, Hotels.com and Viaplay.

Mecenat’s services are primarily digital, allowing for a two-way exchange between brands and members through its app and website. In recent years, the Group has expanded through the acquisitions of Seniordays in 2021, Frank Students in 2022, and Traineeguiden in 2023. The development of the platform in this way has enabled Mecenat to leverage a unique member acquisition approach which sees students entering organically before automatically progressing to alumni, while retaining members throughout their life by leveraging the top-of-mind habit developed when they were students.

Since IK first invested in the business in September 2021, Mecenat has more than doubled its revenue, proving its resilience in the face of challenging global economic conditions. The Group has also: expanded its product offering to attract a more diverse range of members, including alumni and seniors; achieved meaningful geographic expansion beyond the Swedish market; delivered significant technological developments; and executed strategic acquisitions to support the expansion of the product range. 

Jonas Odéhn, CEO of Mecenat Group, said: “We would like to thank IK for their support during the past three years. This period has seen Mecenat develop into an even stronger business thanks to the hard work and dedication of our employees. The Group has experienced tremendous growth and transformed into a leading marketing technology and brand awareness platform with a unique business model and digital-first approach to fostering brand loyalty. With this solid foundation in place, we look forward to the next chapter which will see us partner with the team at Inflexion.”

Carl Jakobsson, Partner at IK Partners and Advisor to the IK SC II Fund, added: “Since investing in Mecenat in 2021, we have been extremely impressed with the professionalism and expertise displayed by Jonas and his team. During our partnership with them, the Group has gone from strength-to-strength, nearly doubling its member base and pursuing geographic expansion through a range of value creation initiatives. We wish Jonas, his team and Inflexion the very best of luck for the next stage in Mecenat’s growth journey.”

For further questions, please contact:

IK Partners
Vidya Verlkumar
Phone: +44 (0)7787 558 193
vidya.verlkumar@ikpartners.com

Paris, 19 December 2024

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible) and EB Development announce the final outcome of the takeover bid initiated by EB Development (the “Offer“), based on the results published on 18 December by the Autorité des marchés financiers (AMF) at the end of the reopening period of the Offer (the “Reopened Offer“).

644,911 ordinary shares were tendered to the Reopened Offer, which closed on 17 December 2024. These are in addition to the 4,582,971 ordinary shares tendered to the Initial Offer, giving a total of 5,227,882 ordinary shares tendered to the Offer, enabling EB Development, acting in conjunction with funds managed by NextStage AM and IK Partners, and Mr. Denis Fortier, Chairman and CEO, and other members of the Board of Directors and senior management of the Company ,[1] to hold, after assimilation of the treasury shares held by Eurobio Scientific (the “Company“), 9,113,592 shares representing 88.92% of the share capital and voting rights of the Company.

As the percentage of share capital and voting rights attained following the Reopened Offer is below the 90% threshold allowing the implementation of a squeeze-out procedure, the additional price of €1.25 per share will not be paid. Settlement and delivery will take place on 23 December 2024.

Denis Fortier, Chairman and CEO of Eurobio Scientific, said: “The results of the takeover bid give Eurobio Scientific the means to accelerate its development with the support of NextStage and now IK Partners, active shareholders who share our strategy and have a good knowledge of our in vitro diagnostics and intelligent health markets. We would like to thank our shareholders for their confidence and support in making this transaction a success.”

NextStage AM acquired a stake in Eurobio Scientific on 18 May 2022 through the creation of a joint holding company with the entrepreneurs called “EurobioNext”. NextStage AM invested in the company through the “Pépites et Territoires” programme by AXA France & NextStage AM and its NextStage EverGreen vehicle.  NextStage AM has supported Eurobio Scientific in structuring its management team and accelerating its external growth strategy, in particular, through significant M&A transactions (including the acquisition of the Dutch company GenDx, one of the world leaders in HLA typing for transplant compatibility, in August 2022).[2]

NextStage AM and IK Partners, as core shareholders, will continue to support the group’s team of entrepreneurs in this new stage of the Company’s growth.

Grégoire Sentilhes, Chairman and co-founder of NextStage AM, commented: “Since May 2022, the team of entrepreneurs led by Denis Fortier has accelerated the transformation of the group post-Covid, in particular through the acquisition of GenDx, by strengthening the part of its business dedicated to proprietary products. We are delighted to be pursuing the development of Eurobio Scientific, which has the potential to become a leading SME in its market, alongside IK Partners, a leading investor who shares our vision and entrepreneurial values.”

Rémi Buttiaux, Managing Partner at IK Partners, added: “Eurobio Scientific has established itself as a market leader in the field of in vitro diagnostics and we are looking forward to working closely with the management team, NextStage AM and other stakeholders to support this next phase of development for the business.”

Warning:

This press release has been prepared for information purposes only. It does not constitute an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. or an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. The release, publication or distribution of this press release may be restricted by law in certain jurisdictions and, accordingly, persons in possession of this press release in such jurisdictions should inform themselves of and observe any applicable legal restrictions. Investors and shareholders in France are strongly advised to read the Offer documents referred to in this announcement as they contain important information about the proposed transaction and other related matters. EB Development’s offer document and “other information” document are available on the websites of the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) and may be obtained free of charge on request from EB Development (43, avenue de Friedland, 75008 Paris, Crédit Industriel et Commercial (6, avenue de Provence, 75009 Paris) and Degroof Petercam Wealth Management (44, rue de Lisbonne, 75008 Paris). Eurobio Scientific’s note in response and “other information” document are available on the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) websites and may be obtained free of charge on request from Eurobio Scientific S.A. (7, avenue de Scandinavie, ZA de Courtaboeuf, 91953 Les Ulis). Neither Eurobio Scientific S.A., EB Development, nor their respective shareholders, advisers or representatives accept any liability whatsoever in connection with the use by any person of this press release or its contents, or more generally in connection with this press release.

[1] Denis Fortier (Chairman and Chief Executive Officer), Cathie Marsais (Chief Operating Officer), Olivier Bosc (Chief Operating Officer), Jean-Michel Carle-Grandmougin (Chief Operating Officer and member of the Board of Directors) and Hervé Duchesne de Lamotte (member of the Board of Directors).

[2] https://nextstage-am.com/eurobio-scientific-participation-de-nextstage-am-annonce-la-signature-dun-accord-en-vue-dacquerir-gendx-leader-mondial-du-diagnostic-hla-aux-pays-bas/

For further questions, please contact:

Eurobio Scientific Group
Denis Fortier, Chairman and CEO
Olivier Bosc, Managing Director / CFO
Tel. +33 1 69 79 64 80

Calyptus
Mathieu Calleux
Investor Relations
Tel. +33 1 53 65 68 68
eurobio-scientific@calyptus.net

IK Partners
Vidya Verlkumar – vidya.verlkumar@ikpartners.com – +44 (0) 7787 558 193

IK Partners (“IK”) is pleased to announce that the IK X Fund has signed an agreement to invest in Dains Accountants (“Dains” or “the Company”), a leading provider of accountancy and business advisory services in the UK, alongside the management team who are significantly re-investing. IK will succeed Horizon Capital as the majority shareholder. Financial terms of the transaction are not disclosed.

Established in 1926, Dains provides a comprehensive suite of accounting and business advisory services to fast-growing small and medium-sized enterprises (“SMEs”) in the UK and Ireland. The business offers a differentiated approach through its senior-led client relationships and high-quality service delivery across its range of services, including: Accountancy & Business Advisory; Audit; Tax; Corporate Finance; Forensic Accounting; and Business Recovery.

Following investment from Horizon Capital in 2021, Dains has grown rapidly as a result of 10 strategic acquisitions and impressive organic growth. At present, the Company has 765 employees who serve a large and diversified customer base of over 17,000 clients.

With the support of IK, Dains will look to: continue its strong organic growth in the UK and Ireland; make further investment in its operational platform and recruitment; as well as accelerate its inorganic growth through partnering with strong, complementary firms across the UK and Ireland.

Richard McNeilly, CEO of Dains, said: “We are very excited to be partnering with IK, who we believe possesses the necessary track record and expertise required to successfully support us in this next phase of our development. The team’s experience in both the Accounting and Professional Services sector, as well as in executing buy-and-build strategies in the UK and Ireland will be especially important in a fragmented marketplace like ours, where we are looking to drive consolidation and reinforce our strong position as the acquiror of choice. We would also like to take this opportunity to thank Luke and his team at Horizon Capital for their unwavering support over the past three years.”

Pete Wilson, Partner at IK Partners and Advisor to IK X Fund, said: “Dains is a strong business with an impressive history of delivering exceptional client services and business growth year on year. The breadth of services offered by their accountancy experts across the UK and Ireland has built an excellent reputation for Dains amongst fast-growing SMEs. With our track record in supporting similar businesses in the Business Services sector, we look forward to partnering with Richard and his team in the next phase of the Company’s journey.”

Luke Kingston, Managing Partner at Horizon Capital, added: “We are so proud to have played a part in the growth of Dains over the last three years and to have backed Richard and his team to build a leading business in its niche. This was a fantastic investment and we are thrilled to have delivered an excellent outcome for all stakeholders involved. We wish the Company every success in the future.”

For further questions, please contact:

IK Partners
Vidya Verlkumar
Head of Communications and Marketing
Phone: +44 7787 558 193
vidya.verlkumar@ikpartners.com

Horizon Capital
Luke Kingston
Managing Partner
Phone: +44 7980 223 458
lk@horizoncapital.co.uk

Rivean Capital (“Rivean”) is pleased to announce that it has signed a definitive agreement to acquire a majority stake in Acture Group (“Acture” or “the Group”), a leading provider of holistic employee welfare solutions, from IK Partners (“IK”). The stake is being acquired from the IK Small Cap II (“IK SC II”) Fund, with Co-Founder and current CEO Maudie Derks, as well as the management team, reinvesting alongside Rivean.

Founded in 2008 and headquartered in Nijmegen, the Netherlands, Acture is a specialised outsourced service provider supporting corporates and staffing agencies in managing employee absence. The Group has an integrated approach to employee welfare, offering complementary services such as absence management and reduction, including case management and reintegration programmes, combined with an absence insurance proposition.

Acture’s heritage and longstanding experience as a pioneer in the private social security services market in the Netherlands have resulted in large amounts of valuable data being translated into innovative case management solutions supported by proprietary technology. With IK’s support since 2020, the Group completed four add-on acquisitions in the Netherlands and three in Germany, to further complement its proposition and expand its geographical footprint. Acture is also currently rolling out a mental health absence management platform, Evermood, in the Netherlands and the DACH region. Through its full-service offering, Acture is well positioned to fully unburden customers who are confronted with labour market shortages and rising absenteeism costs. At present, the Group employs approximately 390 full-time employees across its offices in the Netherlands and Germany.

Ready for the next phase of growth

The Group’s ambition to reinforce its position as a leading European provider of specialised outsourced services and insurance products requires further investment in the organisation to help develop its digital offering and platform capabilities. With Rivean’s support, Acture will continue along its international growth trajectory, accelerating the execution of its strategic growth plan and transforming from a leading Dutch player in the social security market, to a European total employee welfare platform.

Maudie Derks, CEO of Acture, said: “With the recent add-on acquisitions, Acture has taken its first steps into the international arena while simultaneously expanding its offering with a tech-driven wellbeing proposition. Through the new partnership with Rivean, we plan to accelerate our international roll-out, advance our ambitious growth trajectory and further develop the total employee welfare management concept. We would like to thank IK for their support over the past few years and look forward to joining forces with Rivean.”

Nikolai Pronk, Managing Partner at Rivean Capital, commented: “We are very impressed by Acture’s leading market position, supporting its customers with an integrated offering and with a track record of consistent growth. We look forward to partnering with Maudie and the management team to support Acture in its next development and international growth phase.”

Sander van Vreumingen, Partner at IK and Advisor to the IK SC II Fund, added: “Over the past four years, we have had the pleasure of working very closely with Maudie and her team. From the start, we have been impressed with the combined professionalism and expertise of the team, which has enabled both the successful implementation of multiple organic growth initiatives and execution of several bolt-on acquisitions. We are proud of all that we have achieved in partnership with Acture and would like to wish Maudie and her team all the very best in the next stage of their journey.”

Completion of the transaction is subject to obtaining merger clearance, AFM and works council approval.

For further questions, please contact:

Rivean Capital
Maikel Wieland
Partner – Head of Investor Relations & Co-Investments
Phone: +41 43 268 20 30
m.wieland@riveancapital.com

IK Partners
Vidya Verlkumar
Head of Communications and Marketing
Phone: +44 7787 558 193
vidya.verlkumar@ikpartners.com

We are pleased to share our 2023/2024 Sustainability Report “Creating Value with Responsibility”.

This report provides insights into how we integrate sustainability considerations in both value creation and protection activities, in line with our fiduciary duties. It also shines a spotlight on best practice examples from companies within our portfolio.

Our most notable highlights and achievements include:

• Developing a new ESG Roadmap for 2024-2025;
• Implementing a tool to conduct portfolio-wide climate and biodiversity risks screening;
• Publishing our inaugural Task Force on Climate-related Financial Disclosures Report; and
• Becoming an Early Adopter of the Taskforce on Nature-related Financial Disclosures.

To read more, please download the report using the button on the left.

If you have any questions, please contact:

ESG
esg@ikpartners.com